AYTU BIOPHARMA, INC

AYTU · Nasdaq · SIC 2834: Pharmaceutical Preparations · Market Cap: $0.0B · 83 employees
373
SEC Filings
$2.15
Close 2026-06-01
83
Employees

Business Summary

Aytu BioPharma, Inc. is a pharmaceutical company focused on innovative medicines for central nervous system diseases. It commercializes EXXUA (gepirone) for major depressive disorder, and ADHD products Adzenys XR-ODT and Cotempla XR-ODT, plus allergy/supplement products Karbinal ER, Poly-Vi-Flor, and Tri-Vi-Flor. The company licenses, acquires, develops, and commercializes novel prescription therapeutics, selling primarily through third-party wholesalers and pharmacies in the United States.

Latest Stock Quote

AYTU 2026-06-01 $2.15 O:$2.25 H:$2.2899 L:$2.1055 Vol:0.1M VWAP:$2.2065
origin leaf: 2ac1c68122c2bb5006743b4ec439e013d3cafe2535af8034101e79ab88bb58f3

Next Earnings

Q2 FY2026 — expected 2026-09-18

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2025-09-232025-06-300001437749-25-029723EDGAR67K words
2024-09-262024-06-300001437749-24-030062EDGAR—
2023-10-122023-06-300001558370-23-016393EDGAR—
2022-09-272022-06-300001558370-22-014652EDGAR—
2021-09-282021-06-300001558370-21-012825EDGAR—
2020-10-062020-06-300001654954-20-010891EDGAR—
2019-09-262019-06-300001654954-19-011147EDGAR—
2018-09-062018-06-300001213900-18-012209EDGAR—
2017-08-312017-06-300001144204-17-046061EDGAR—
2016-09-012016-06-300001144204-16-122393EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-02-032025-12-310001437749-26-002804EDGAR25K words
2025-11-132025-09-300001437749-25-034825EDGAR—
2025-05-142025-03-310001437749-25-016833EDGAR—
2025-02-122024-12-310001437749-25-003568EDGAR—
2024-11-132024-09-300001437749-24-034970EDGAR—
2024-05-152024-03-310001437749-24-017051EDGAR—
2024-02-142023-12-310001437749-24-004149EDGAR—
2023-11-142023-09-300001558370-23-019015EDGAR—
2023-05-112023-03-310001558370-23-009367EDGAR—
2023-02-212022-12-310001558370-23-001645EDGAR—
2022-11-142022-09-300001558370-22-017751EDGAR—
2022-05-162022-03-310001558370-22-008952EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001437749-26-011116EDGAR13K words
2026-02-030001437749-26-002799EDGAR—
2026-01-200001437749-26-001543EDGAR—
2025-12-100001437749-25-037389EDGAR—
2025-11-130001437749-25-034822EDGAR—
2025-09-230001437749-25-029721EDGAR—
2025-08-070001437749-25-025441EDGAR—
2025-06-230001437749-25-020973EDGAR—
2025-06-170001437749-25-020579EDGAR—
2025-06-090001437749-25-019868EDGAR—

373 total filings indexed. 341 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Tags

central-nervous-system-diseases major-depressive-disorder attention-deficit-hyperactivity-disorder-(adhd) allergic-conditions pediatric-prescription-pharmaceuticals

Company Identity

CIK0001385818
TickerAYTU
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE
HeadquartersDenver, Colorado
Websitehttps://www.aytubio.com
Listed2008-02-15

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 7284c4d01a6c4ce7fdc89d8b13f8335d09866f62db73c39b68ac4feb2009b721
parent: 534b5defa44d4dd147ed11a9ae862af66746f9968c3787c30cbe646c3203cacb
content hash: 5dd26b954420d6cc0d05fb1ef32cc5a23462b4cf7b7bf6e4aae8777f3207baa0
signed: 2026-06-03T12:00:20.400Z
sources: 23 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf